Sell AstraZeneca, says UBS, which upgrades European rivals including GSK
By Steve Goldstein
UBS analysts shook up their ratings of European drugmakers, including making a double-downgrade of AstraZeneca and a double-upgrade of U.K. rival GSK.
UBS took its ratings on AstraZeneca (UK:AZN) (AZN) to sell from buy, while it upgraded GSK (UK:GSK) (GSK)to buy from sell. It also upped Novartis (CH:NOVN) (NVS) and Sanofi (FR:SAN) (SNY) to buy from neutral, and Novo Nordisk (DK:NOVO.B) (NVS) to neutral from sell.
Analysts led by Matthew Weston say sector valuations are not demanding excluding weight-loss drug maker Novo Nordisk, trading at 13.8 times projected 2024 earnings ex the Danish drugmaker.
On GSK, it forecasts Shingrix sales significantly ahead of consensus, buoyed by a recent China deal. UBS also is more positive on Novartis cancer, chronic spontaneous urticaria and MS drugs than consensus. It is worried about AstraZeneca's exposure to Medicare Part D reform, particularly its oral oncology portfolio.
On Novo Nordisk, "while we can justify current levels based on growth and earnings momentum, we struggle to stretch the valuation further to justify a more positive stance," the analysts said.
AstraZeneca shares slumped 3% in London, while the other pharma stocks saw limited moves.
-Steve Goldstein
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
01-16-24 0534ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
The Best REITs to Buy
-
3 Hot Stocks to Buy That Still Look Undervalued
-
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy